Ocrevus Has Received Pediatric Approval Recommendation
The EMA recommended Ocrevus for patients aged 10 and older with relapsing forms of multiple sclerosis.
Updated on Sept. 22, 2026 in Stroke
Live Poll
Should regulators approve high-efficacy drugs for children based on adult trial data and limited pediatric studies?
European regulators have recommended extending the use of Ocrevus to pediatric patients aged 10 and older with relapsing forms of multiple sclerosis (RMS). This milestone follows a positive review by the Committee for Medicinal Products for Human Use (CHMP) and awaits final authorization from the European Commission.
Why it matters
Extending this treatment to younger patients could provide a new therapeutic option to manage inflammatory activity and disease progression in children living with multiple sclerosis. If approved, this authorization represents a shift in standard care for pediatric-onset RMS cases within the European Union.
The recommendation is supported by the Phase 3 OPERETTA 2 trial, which evaluated 187 patients aged 10 to 17 years with pediatric-onset relapsing-remitting multiple sclerosis. Researchers compared the efficacy of intravenous ocrelizumab against fingolimod in this adolescent cohort.
The players
European Medicines Agency
The European Union regulatory agency responsible for evaluating the safety and efficacy of medicinal products.
Committee for Medicinal Products for Human Use
The expert committee within the European Medicines Agency that issues recommendations on marketing authorization for medicines.
European Commission
The executive branch of the European Union that grants final marketing authorizations for medical products.
The details
Ocrelizumab is a monoclonal antibody that works by targeting the CD20 protein found on B cells. By depleting these CD20-positive cells, the drug reduces inflammatory activity in the central nervous system. This process is intended to help limit the frequency of relapses and slow disease progression, and it is administered to patients via intravenous infusion.
Timeline
September 22, 2026: The regulatory recommendation was announced.
Health Landscape
This development follows the findings of the OPERETTA 2 trial to expand the eligible patient population for advanced MS therapies. It marks a shift toward broader access to B-cell-depleting monoclonal antibodies for pediatric-onset relapsing-remitting multiple sclerosis.
Parents and caregivers of children with relapsing multiple sclerosis should monitor the European Commission's forthcoming decision on this treatment. It is worth discussing with a pediatric neurologist whether this infusion-based therapy may be appropriate for an individual care plan.
The takeaway
The move to approve Ocrevus for younger patients highlights the growing focus on treating pediatric-onset multiple sclerosis with B-cell-targeted therapies. If you are managing this condition, ask your specialist about the latest eligibility criteria and available clinical options for adolescents.
Further reading
For more on managing complex neurological conditions, explore the Stroke section.
Source note: This article includes information reported by Medscape.
Live Poll
Should regulators approve high-efficacy drugs for children based on adult trial data and limited pediatric studies?
